What is the 13F Pro Quality Score for PTGX?

13F Pro ranks Protagonist Therapeutics, Inc (PTGX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PTGX's current score at https://13fpro.ai/company/PTGX (free sign-up required for the full ranking).

Which hedge funds own the most PTGX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PTGX include BlackRock,, FARALLON CAPITAL MANAGEMENT, RTW INVESTMENTS,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/PTGX as soon as new 13F filings post.

Where does 13F Pro source PTGX data?

All Protagonist Therapeutics, Inc fundamentals and ownership data come directly from SEC EDGAR. Protagonist Therapeutics, Inc files with the SEC under CIK 1377121. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PTGX in?

Protagonist Therapeutics, Inc (PTGX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives PTGX's revenue?

Per Protagonist Therapeutics, Inc's latest 10-Q filed with the SEC on 2026-08-05, the biggest revenue drivers are: Takeda Collaboration Agreement opt-out payment recognition ($192.4M, New in Q2 2026); Takeda development services, clinical supplies and other ($21.1M, New in Q2 2026). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/PTGX.

What are PTGX's largest expenses?

Protagonist Therapeutics, Inc's latest 10-Q reports these as the largest expense items: Research and development ($42.1M, +14% YoY); General and administrative ($12.6M, +20% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is PTGX research updated on 13F Pro?

PTGX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Protagonist Therapeutics, Inc(PTGX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1377121 PTGX stock profile & AI dashboard →

13F Pro Quality Score

59.4/100

Rank #931 of 2,961 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

39.8/100

Profitability

91.8/100

Balance Sheet

86.0/100

Earnings Quality

76.5/100

Free Cash Flow

93.6/100

Institutional Flow

35.4/100

Revenue Scale

28.5/100

Dilution Risk

3.1/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why PTGX Scores 59/100

exact factor attribution · 2026-09-11

PTGX's composite is driven by free cash flow and profitability, held back by scale and shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Free cash flow

+6.5 pts

94th pct

Profitability

+6.3 pts

92th pct

Capital efficiency

+3.6 pts

86th pct

Earnings quality

+2.6 pts

77th pct

Institutional flow

-0.7 pts

35th pct

Earnings growth

-1.3 pts

24th pct

Revenue growth

-2.0 pts

40th pct

Shareholder dilution

-2.4 pts

3th pct

Scale

-3.2 pts

29th pct

Latest change (2026-08-05): 25 → 27 · ↑ Revenue growth 2→92; despite ↓ Free cash flow 92→3

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

PTGX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Protagonist Therapeutics, Inc (PTGX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PTGX at 59.4/100 on a 32-signal composite quality model, placing it at rank #931 of 2,961 stocks — the top half of the AI-ranked universe. PTGX scores in the top quartile across free cash flow (93.6), profitability (91.8), balance sheet strength (86.0). Areas of concern include revenue scale (28.5) and institutional flow (35.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Protagonist Therapeutics, Inc reports quarterly revenue of $213.5M, net income of $162.8M, free cash flow of $218.9M. Top institutional holders of PTGX by reported 13-F value include BlackRock, FARALLON CAPITAL MANAGEMENT, RTW INVESTMENTS, based on the most recent SEC filings. PTGX trades on the Nasdaq exchange and files with the SEC under CIK 1377121. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PTGX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Protagonist Therapeutics, Inc directly from SEC EDGAR. Protagonist Therapeutics, Inc's 13F Pro composite quality score has ranged between 10 and 59 since 2026, currently 59.4 — an improving long-term trajectory across 48 quarterly and live scoring snapshots.

✦

Fun facts about Protagonist Therapeutics, Inc

Quirks, history, and lore behind PTGX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in the San Francisco Bay Area · focused on peptide-based medicines.
2
The Numbers
A pre-revenue biotech with a market cap in the low hundreds of millions — its balance sheet is more about R&D burn rate than sales figures.
3
The History
Founded in the mid-2010s, the company was built around proprietary technology for engineering peptide analogs that mimic or block natural gut hormone signals.
4
The Secret
Its pipeline targets hematologic diseases and gastrointestinal disorders — including rare blood conditions driven by overactive hormone receptors in the gut.
5
The Lore
The company's lead programs have targeted polycythemia vera and iron-deficiency anemia, chasing a class of drugs that modulate hepcidin — the master regulator of iron in the body.
6
The Giveaway
Its very name declares its mission: be the hero of the story in drug discovery — a peptide-focused biotech whose ticker and name both put the protagonist front and center.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving PTGX's Business? Latest 10-Q Breakdown

AI-extracted from Protagonist Therapeutics, Inc's 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

License and collaboration revenue surged to $213.5M in Q2 2026, driven by $200M opt-out payment recognition from Takeda and $50M ICOTYDE FDA approval milestone from JNJ, swinging to $162.8M net income from $34.8M loss year-over-year.

Biggest Revenue Drivers

Takeda Collaboration Agreement opt-out payment recognition$192.4MNew in Q2 2026

Proportional recognition of $200M opt-out payment triggered by exercise of profit-share opt-out right on April 28, 2026

Takeda development services, clinical supplies and other$21.1MNew in Q2 2026

Cost reimbursement for post opt-out wind-down services and rusfertide clinical supplies

Biggest Revenue Drivers

Takeda Collaboration Agreement opt-out payment recognition$192.4MNew in Q2 2026

Proportional recognition of $200M opt-out payment triggered by exercise of profit-share opt-out right on April 28, 2026

Takeda development services, clinical supplies and other$21.1MNew in Q2 2026

Cost reimbursement for post opt-out wind-down services and rusfertide clinical supplies

Largest Expense Items

Research and development$42.1M+14% YoY

Increase driven by PN-881 Phase 1 trial costs ($8.6M), pre-clinical discovery programs ($8.4M), partially offset by rusfertide completion ($12.0M reduction)

General and administrative$12.6M+20% YoY

Increase primarily from personnel-related expenses driven by wage, benefit and stock-based compensation increases

Watch Items from the Filing

Substantial revenue concentration: Q2 revenue of $213.5M is almost entirely from two collaboration partners (Takeda and JNJ); future revenue highly dependent on their regulatory approvals and commercial success.
Company expects R&D expenses to increase significantly in H2 2026 due to PN-881 Phase 2b psoriasis advancement, manufacturing investments, and multiple program initiations (PN-477sc, PN-458, PN-8047).

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$213.5M

Net Income

Q2 2026

$162.8M

Free Cash Flow

Q2 2026

$218.9M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-89.4% YoY

$46.0MFY 2025

FY22 $26.6MFY23 $60.0MFY24 $434.4MFY25 $46.0M

Net Income

-147.3% YoY

$-130.1MFY 2025

FY22 $-127.4MFY23 $-79.0MFY24 $275.2MFY25 $-130.1M

Operating Income

-162.5% YoY

$-158.1MFY 2025

FY22 $-131.4MFY23 $-93.7MFY24 $252.8MFY25 $-158.1M

EPS (Diluted)

-148.5% YoY

$-2.05FY 2025

FY22 $-2.60FY23 $-1.39FY24 $4.23FY25 $-2.05

Total Assets

-10.3% YoY

$668.2MFY 2025

FY22 $247.9MFY23 $358.0MFY24 $744.7MFY25 $668.2M

Op. Cash Flow

-68.7% YoY

$57.7MFY 2025

FY22 $-108.1MFY23 $-70.2MFY24 $184.2MFY25 $57.7M

Free Cash Flow

-69.3% YoY

$56.1MFY 2025

FY22 $-108.9MFY23 $-70.8MFY24 $182.8MFY25 $56.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$46.0M -89.4%	$434.4M +624.1%	$60.0M +125.7%	$26.6M -2.8%	$27.4M -4.4%	$28.6M
Net Income	$-130.1M -147.3%	$275.2M +448.5%	$-79.0M +38.0%	$-127.4M -1.5%	$-125.6M -89.8%	$-66.2M
Operating Income	$-158.1M -162.5%	$252.8M +370.0%	$-93.7M +28.7%	$-131.4M -4.4%	$-125.8M -95.1%	$-64.5M
EPS (Diluted)	$-2.05 -148.5%	$4.23 +404.3%	$-1.39 +46.5%	$-2.60 +4.1%	$-2.71 -41.1%	$-1.92
Total Assets	$668.2M -10.3%	$744.7M +108.1%	$358.0M +44.4%	$247.9M -28.7%	$347.7M +7.2%	$324.5M
Operating Cash Flow	$57.7M -68.7%	$184.2M +362.2%	$-70.2M +35.0%	$-108.1M -0.3%	$-107.9M -48.8%	$-72.5M
Free Cash Flow	$56.1M -69.3%	$182.8M +358.0%	$-70.8M +35.0%	$-108.9M +0.0%	$-109.0M -49.4%	$-73.0M

Get alerted when PTGX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Protagonist Therapeutics, Inc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PTGX

BlackRock, Inc.
$1.3B10,307,837 sh
FARALLON CAPITAL MANAGEMENT LLC
$778.2M6,348,906 sh
RTW INVESTMENTS, LP
$620.4M5,061,175 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$444.9M3,629,298 sh
WELLINGTON MANAGEMENT GROUP LLP
$418.8M3,416,781 sh
UBS Group AG
$416.7M3,399,221 sh
STATE STREET CORP
$407.2M3,321,554 sh
VANGUARD CAPITAL MANAGEMENT LLC
$349.8M2,853,394 sh
JOHNSON & JOHNSON
$300.2M2,449,183 sh
Invesco Ltd.
$286.9M2,340,667 sh

Fund	Value	Shares
BlackRock, Inc.	$1.3B	10,307,837
FARALLON CAPITAL MANAGEMENT LLC	$778.2M	6,348,906
RTW INVESTMENTS, LP	$620.4M	5,061,175
VANGUARD PORTFOLIO MANAGEMENT LLC	$444.9M	3,629,298
WELLINGTON MANAGEMENT GROUP LLP	$418.8M	3,416,781
UBS Group AG	$416.7M	3,399,221
STATE STREET CORP	$407.2M	3,321,554
VANGUARD CAPITAL MANAGEMENT LLC	$349.8M	2,853,394
JOHNSON & JOHNSON	$300.2M	2,449,183
Invesco Ltd.	$286.9M	2,340,667

Companies Similar to PTGX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ALKS

Alkermes plc.

AI score

Similar quality profile · 23 shared holders

RTW INVESTMENTS, LP DRIEHAUS CAPITAL MANAGEMENT LLC SEGALL BRYANT & HAMILL, LLC

ADMA

ADMA BIOLOGICS, INC.

AI score

Similar quality profile · 16 shared holders

Duquesne Family Office LLC KENNEDY CAPITAL MANAGEMENT LLC Virtus Investment Advisers, LLC

UTHR

UNITED THERAPEUTICS Corp

AI score

Similar quality profile · 11 shared holders

LORD, ABBETT & CO. LLC AXIOM INVESTORS LLC /DE NORDEA INVESTMENT MANAGEMENT AB

CGEN

COMPUGEN LTD

AI score

Similar quality profile · 1 shared holders

AXQ CAPITAL, LP

LNTH

Lantheus Holdings, Inc.

AI score

Similar quality profile · 11 shared holders

FARALLON CAPITAL MANAGEMENT LLC SILVERCREST ASSET MANAGEMENT GROUP LLC NORDEA INVESTMENT MANAGEMENT AB

AMPH

Amphastar Pharmaceuticals, Inc.

AI score

Similar quality profile · 6 shared holders

NORDEA INVESTMENT MANAGEMENT AB SEGALL BRYANT & HAMILL, LLC China Universal Asset Management Co., Ltd.

FBIO

Fortress Biotech, Inc.

AI score

Similar quality profile · 2 shared holders

Opaleye Management Inc.Axiom Investment Management LLC

PBYI

PUMA BIOTECHNOLOGY, INC.

AI score

Similar quality profile · 4 shared holders

KENNEDY CAPITAL MANAGEMENT LLC Abel Hall, LLC China Universal Asset Management Co., Ltd.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PTGX on your watchlist

Track score changes the day Protagonist Therapeutics, Inc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PTGX a good stock to buy?

13F Pro's AI-powered analysis of Protagonist Therapeutics, Inc (PTGX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PTGX are available on the PTGX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PTGX is classified as a mid company.

Which hedge funds own PTGX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PTGX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Protagonist Therapeutics, Inc's investment landscape.